Why the study?
Does dabigatran reduce stroke- and bleed-related healthcare resource utilization and costs compared to rivaroxaban or warfarin in adult patients with newly diagnosed non-valvular atrial fibrillation?
Does dabigatran reduce stroke- and bleed-related healthcare resource utilization and costs compared to rivaroxaban or warfarin in adult patients with newly diagnosed non-valvular atrial fibrillation?
Answers are grounded in this paper and cite their sources.
In a real-world cohort of patients with non-valvular atrial fibrillation, dabigatran was associated with lower bleed-related healthcare resource utilization and costs compared to rivaroxaban and warfarin.
BACKGROUND: This is one of the first head-to-head real-world evidence studies comparing stroke-related and bleed-related healthcare and resource utilization (HCRU) and costs among non-valvular atrial fibrillation (NVAF) patients initiating oral anticoagulants. METHODS: Adult NVAF patients newly diagnosed and treated with dabigatran, rivaroxaban, or warfarin between 10/01/2010 and 12/31/2014 were identified using MarketScan Commercial and Medicare Supplemental databases. Per-patient-per-month stroke and bleed-related HCRU and costs were reported. RESULTS: Dabigatran patients were matched 1:1 to 26,592 rivaroxaban and 33,024 warfarin patients (mean age=68 years). Compared to rivaroxaban, dabigatran patients had lower bleed-related inpatient and outpatient HCRU (0.004 vs. 0.005; 0.099 vs. 0.145) and significantly lower adjusted bleed-related costs ($116 vs. $172), all p <0.05. Compared to warfarin, dabigatran patients had significantly lower stroke-related outpatient visits (0.034 vs. 0.048, p<0.001) and higher bleed-related outpatient visits (0.101 vs. 0.091, p=0.045). Multivariate adjusted bleed-related costs were significantly lower for dabigatran patients than warfarin patients ($94 vs. $138, p<0.001). CONCLUSIONS: The results suggest that dabigatran patients had lower bleed-related HCRU and costs than rivaroxaban patients, and lower outpatient stroke-related HCRU, higher bleed-related outpatient HCRU, and lower bleed-related costs than warfarin patients. It provides valuable stroke-related and bleed-related HCRU and costs information among commercially insured and Medicare patients.
No takes yet. Share an insight, caveat, or question.
Gilligan et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: